- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
DBVT
NASDAQ
Week ended 11 Sep 2026
Weekly Investor Report
DBV Technologies · Healthcare · Biotechnology
Latest close
11.85 USD
-12.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -32.1% below the Trend Line and sits at 17.3% of its 52-week range. The latest completed week returned -12.0%, after a -15.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 68/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: earnings are due in 38d.
Setup score
25
out of 100
Latest Close
11.85 USD
11 Sep 2026
1W Return
-12.0%
latest completed week
4W Return
-15.5%
short-term follow-through
12W Return
-23.7%
quarterly tape
Trend Breadth
69.2%
36 of 52 weeks active
Volume Ratio
2.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 40.22% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-12.0%
Latest completed week; four-week move -15.5%.
Indicator stack
38/27
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.22%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
68/100 conviction; expected move 30.4%.
News sentiment
50/100
9 relevant articles in the latest sentiment read.
Event risk
38d
Next report is scheduled for 27 Oct 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -32.1% below the Trend Line and sits at 17.3% of its 52-week range. The latest completed week returned -12.0%, after a -15.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.11
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -15.5% over four weeks, -23.7% over 12 weeks, and 20.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year36
Trend breadth69.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.39Latest activity-pressure read.
Pressure change19.6%Four-week change in activity pressure.
Leadership-37.87Latest relative-leadership reading.
RS change-36.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 11 Sep 2026
Financial statements through 30 Jun 2026
Field coverage 61%
Model confidence 61%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength21/100Blend of value, momentum, and quality. Underlying universe rank 80; rank 1 is best.
Value36/100Relative valuation strength. Underlying universe rank 65; rank 1 is best.
Quality34/100Profitability and accounting quality. Underlying universe rank 67; rank 1 is best.
Momentum36/100Medium-term price momentum. Underlying universe rank 65; rank 1 is best.
Growth36/100Revenue and earnings growth. Underlying universe rank 65; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -34.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -2090.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
DBVT shows volatility options pressure with a 68/100 conviction score, put-call volume ratio of 2.65, expected move of 30.4%, and Sharemaestro trend signal inactive.
Conviction68/100
Expected move30.4%
Put/call volume2.65
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 9 relevant articles.
2 positive · 4 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings38dNext report is scheduled for 27 Oct 2026; event risk rises as the date approaches.
Options expected move30.4%Nearest-chain priced movement where available.
52-week drawdown-54.7%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
20 Mar
17 Apr
15 May
12 Jun
10 Jul
7 Aug
11 Sep
Weeks higher10 of 2616 weeks finished lower.
Best week+5.3%Week of 3 Apr.
Worst week-13.1%Week of 5 Jun.
Latest week-12.0%Week of 11 Sep.
Shape of recent returns
Strong gains6
Modest gains4
Flat weeks0
Modest losses7
Sharp losses9
Recent vol5.8%13-week weekly-return volatility.
Base vol11.0%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew10.6% / -5.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average0.6%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD69.0%positive activity pressure
RS53.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-0.7%
Trend breadth76.0%
Trend76.0%active weekly trend signals
MD69.0%positive activity pressure
RS61.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape29/100
Trend, activity pressure, participation, and risk combine to a 29/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.02; No reversal markers Next-Week ExpectancyNegative 40.22%Next-week expectancy is negative with a 40.22% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors30/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 55; Small Cap Core rank 65 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options67/100DBVT shows volatility options pressure with a 68/100 conviction score, put-call volume ratio of 2.65, expected move of 30.4%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 30.4% Sentiment50/100Weighted news tone is neutral across 9 relevant articles.
DBVT Slides As DBV Technologies Leads European Biotech Declines Insiders50/100No recent insider transaction evidence is stored.
Earnings38dNext report is scheduled for 27 Oct 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | 11.85 USD | -12.0% | 17.46 USD | 10.33 USD | -1.39 | -37.87 | 3.1M | Off |
| 4 Sep 2026 | 13.47 USD | -0.5% | 17.76 USD | 10.34 USD | -1.54 | -29.80 | 803.8K | Off |
| 28 Aug 2026 | 13.54 USD | -6.9% | 18.02 USD | 10.36 USD | -1.57 | -29.02 | 797.4K | Off |
| 21 Aug 2026 | 14.55 USD | 3.8% | 18.29 USD | 10.37 USD | -1.62 | -23.30 | 855.1K | Off |
| 14 Aug 2026 | 14.02 USD | 4.0% | 18.63 USD | 10.37 USD | -1.73 | -27.73 | 1.4M | Off |
| 7 Aug 2026 | 13.48 USD | -0.1% | 18.85 USD | 10.38 USD | -1.74 | -29.65 | 2.8M | Off |
| 31 Jul 2026 | 13.50 USD | -1.0% | 18.97 USD | 10.39 USD | -1.73 | -25.87 | 2.2M | Off |
| 24 Jul 2026 | 13.63 USD | -7.3% | 19.15 USD | 10.40 USD | -1.72 | -24.57 | 1.4M | Off |
| 17 Jul 2026 | 14.70 USD | -10.9% | 19.34 USD | 10.42 USD | -1.58 | -19.76 | 1.5M | Off |
| 10 Jul 2026 | 16.49 USD | 4.2% | 19.61 USD | 10.43 USD | -1.63 | -13.53 | 923.4K | Off |
| 3 Jul 2026 | 15.82 USD | -1.2% | 19.67 USD | 10.43 USD | -1.59 | -15.34 | 1.2M | Off |
| 26 Jun 2026 | 16.01 USD | 3.1% | 19.61 USD | 10.45 USD | -1.64 | -13.51 | 2.2M | Off |
| 19 Jun 2026 | 15.53 USD | -10.8% | 19.51 USD | 10.46 USD | -1.53 | -19.50 | 882.3K | Off |
| 12 Jun 2026 | 17.42 USD | 5.0% | 19.45 USD | 10.49 USD | -1.43 | -7.10 | 1.7M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.